In this study, we show that the modulation of VLA-4 activity in a variety of tumor cell lines of either solid tumor or leukemic origin by the tellurium compounds SAS or AS101 reduces PD-L1 expression, preventing malignant cells from evading stimulated syngeneic CD8-positive cells. The gene discussed is CD8A; the disease is neoplasm.